Christian Waage 4
4 · HERON THERAPEUTICS, INC. /DE/ · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Heron Therapeutics (HRTX) Director Christian Waage Receives Award
What Happened
Christian Waage, a director of Heron Therapeutics, was granted 53,960 restricted stock units (RSUs) on January 30, 2026. The Form 4 reports an acquisition price of $0.00 per unit (total $0) because these are compensation awards, not purchases. Each RSU represents a contingent right to receive one share of common stock upon vesting.
Key Details
- Transaction date: 2026-01-30; Form 4 filed: 2026-02-03. Transaction code: A (award/grant).
- Grant size: 53,960 RSUs; reported acquisition price: $0.00 per unit (total reported $0).
- Vesting: RSUs vest in full on 2027-01-30 (per footnote). Each RSU equals one share when vested.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- No 10b5-1 plan, tax-withholding sale, or immediate sale reported — this is a time‑vested compensation award.
Context
RSU grants to directors are common as compensation and retention; they do not increase outstanding common shares until they vest and are settled. Because this was an award (not an open‑market purchase or sale), it should be interpreted as compensation rather than a direct insider investment signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-30+53,960→ 53,960 total
Footnotes (1)
- [F1]The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.